

LABORATORY CORP OF AMERICA HOLDINGS  
Form 8-K  
November 05, 2001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange  
Act of 1934  
November 5, 2001

-----

(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----  
(Exact name of registrant as specified in its charter)

|  |                             |  |
|--|-----------------------------|--|
| DELAWARE   | 1-11353                     | 13-3757370                                 |
| -----  | -----                       | -----                                      |
| (State or other<br>jurisdiction of<br>incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification<br>Number) |

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

-----

(Address of principal executive offices)

336-229-1127

-----

(Registrant's telephone number, including area code)

ITEM 9. Regulation FD Disclosure.

Laboratory Corporation of America -Registered Trademark-  
Holdings (LabCorp -Registered Trademark-) (NYSE:LH) announced  
that Thomas P. Mac Mahon, chairman and chief executive  
officer, is scheduled to speak at the CIBC World Markets  
12th Annual Health Care Conference in New York City, NY on  
Tuesday, November 6 at 8:30 a.m. Eastern Time. The  
presentation will be webcast live, with a rebroadcast  
available for 90 days, and may be heard online at  
www.labcorp.com.

At the conference, Mr. Mac Mahon will reiterate Company  
guidance for 2001 and 2002, as filed in an 8K on October 22.  
Mr. Mac Mahon will state, "For 2001, we expect revenue  
growth of 13.5 percent, EBITDA margins of approximately 21  
percent of sales and EPS growth of approximately 55 percent  
compared to 2000. For 2002, we expect to increase overall  
revenues by approximately 12 percent compared to 2001 and we

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

expect EPS growth, as calculated under existing accounting rules, of approximately 33 percent compared to 2001. In calculating earnings and EPS under the new accounting rules regarding goodwill, we expect the non-amortization of goodwill to have an impact of approximately \$26 million in 2002, resulting in an increase to EPS of approximately \$0.36."

Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2000 and subsequent SEC filings.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----  
(Registrant)

By: /s/ BRADFORD T. SMITH

-----  
Bradford T. Smith  
Executive Vice President  
and Secretary

Date: November 5, 2001